Abstract Objective Direct oral anticoagulants (DOACs) have been recommended for the
treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the …

Introduction Post-thrombotic syndrome (PTS) is a chronic complication of deep vein
thrombosis (DVT) that affects 20% to 50% of DVT patients. Standard DVT treatment included …

Introduction Despite treatment of acute deep vein thrombosis (DVT) with low molecular
weight heparin and warfarin, up to 50% of patients develop post-thrombotic syndrome (PTS) …

Introduction Post-thrombotic syndrome (PTS) is a burdensome long-term complication of
deep vein thrombosis (DVT). Recent studies have suggested that rivaroxaban may reduce …

Background: Postthrombotic syndrome (PTS) has a major impact on the quality of life after
deep venous thrombosis (DVT). From clinical practice and related trials, anticoagulants …

Postthrombotic syndrome (PTS) is a frequent complication of venous thromboembolism
(VTE). Using MarketScan claims data from January 2012 to June 2015, we identified adults …

Post-thrombotic syndrome (PTS) is a complication of deep vein thrombosis (DVT). Residual
vein thrombus (RVT) on Doppler Ultrasound can be associated with PTS. Limited data are …

Post-thrombotic syndrome (PTS) is a common complication of deepvein thrombosis (DVT).
Poor quality treatment with vitamin K antagonists (VKA) is a risk factor for PTS. We …

Deep‐vein thrombosis (DVT) can have a significant impact on a patient's life. In particular,
the development of post‐thrombotic syndrome as a long‐term complication of DVT can have …

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to
warfarin reduces the risk of post‐thrombotic syndrome (PTS) after deep vein thrombosis …